Publication | Open Access

CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma

Cell TherapyCancer ImmunosurveillanceImmunologyTumor ImmunityImmune Checkpoint InhibitorAutoimmunityVivo Antitumor ActivityHuman Multiple MyelomaImmunotherapyMedicineCell BiologyTumor BiologySynthetic Immunology